Surbhi Sidana, MD, discusses the key aspects of iberdomide that make the CELMoD's FDA approval so significant for multiple ...

Singhi, MD, and participants discussed how the ROS1 G2032R resistance mutation is guiding second-line therapy selection in ROS1-positive advanced non–small cell lung cancer. After progression on a ...

The Journal of Targeted Therapies in Cancer | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Tumor hypoxia serves as a biologic marker of radioresistance, enabling maintenance of standard-intensity treatment when ...

Dual EGFR/MET blockade aims to counter MET overexpression–associated attenuation of EGFR TKI durability, potentially ...

Learn how oncologists spot burnout early and cut it with smarter workflows, PTO coverage, supportive leadership, and ...

The FDA has approved rusfertide (Mimrylo) for adult patients with polycythemia vera (PV). 1 ...

The OS findings follow the recent FDA approval of zanidatamab with or without tislelizumab in HER2-positive gastroesophageal cancer. Zanidatamab-hrii (Ziihera) plus chemotherapy demonstrated a ...

August 2026 FDA oncology updates: iberdomide, zanidatamab and daraxonrasib win approvals as fast-track designations ...

The FDA has approved ropeginterferon alfa-2b-njft (Besremi) for adults with essential thrombocythemia (ET), marking the first ...

A type C meeting between IDEAYA Biosciences and the FDA has established the design of a phase 3 registrational trial for ...

A gynecologic oncologist unpacks shifting cancer trends, HRD and germline testing, screening pitfalls, and where new ...